Figure 4.

Revised risk classification of acute myeloid leukemia (AML) patients. (A) Mutation profiling of this study, Hou et al.7, and Patel et al.3 for risk stratification of AML patients. (B) Effect of the mutation profiling on the conventional cytogenetic risk. Patients with intermediate‐risk cytogenetic AML who have markedly divergent prognoses are reassigned into the appropriate risk groups according to their mutation profiles. Patients with favorable‐risk cytogenetics and KIT mutation are reclassified as intermediate risk. Overall survival estimated by Kaplan–Meier analysis according to (C) the current integrated stratification system, (D) revised risk system of Patel et al., and (E) risk stratification system of Hou et al.